Recombinant Human Apolipoprotein C-III is produced by our Mammalian expression system and the target gene encoding Ser21-Ala99 is expressed with a human IgG1 Fc tag at the C-terminus.

Apolipoprotein C-III; APOC3; Apolipoprotein C3; ApoC-III; Apo-CIII

37.5 kDa

45-55 kDa, reducing conditions

Supplied as a 0.2 μm filtered solution of PBS, pH7.4.

0

The product is shipped on dry ice pack.Upon receipt, store it immediately at the temperature listed below.

Apolipoprotein C3 (APOC3) is now attracting a surge in interest as a potential new drug target in the prevention of incident or recurring cardiovascular disease (CVD) events. APOC3 is a small (79 amino acids) apolipoprotein produced primarily by the liver and to a lesser extent by the intestine. APOC3 is bound to triglyceride-rich lipoproteins (TRLs), comprised of chylomicrons from the intestine and VLDL from the liver, and to high-density lipoprotein (HDL). APOC3 appears to hold an important role as a CVD risk factor and mediator in people with diabetes, at least in the case of type 1 diabetes, in which plasma triglyceride levels are often within the optimal (<100 mg/dL) to borderline (100-150 mg/dL) range. And APOC3 positively predicts the risk of major CVD events independently of traditional CVD risk factors, such as age, sex, diabetes duration, blood glucose control, blood pressure, smoking, LDL-cholesterol and HDL-cholesterol.